<DOC>
	<DOC>NCT01303172</DOC>
	<brief_summary>To compare, in patients with advanced pancreatic cancer, the effects of IMM-101 in combination with gemcitabine to gemcitabine alone on safety and tolerability (including QoL), clinical signs and symptoms of disease, selected markers of tumour burden and immunological status, and disease outcome.</brief_summary>
	<brief_title>A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically and/or cytologically confirmed inoperable ductal adenocarcinoma of the pancreas, including the mucinous variant. This will include locally advanced and metastatic disease (stage III/IV). Presence of measurable lesions in at least one site which have not been previously irradiated (bone lesions, ascites and pleural effusions are not considered as measurable), described as any of the following: WHO performance status of 02 serum creatinine &lt;140 Î¼mol/L white blood cell (WBC) count, including differential counts within the normal range a life expectancy of &gt;3 months from randomisation acinar cell carcinoma, neuroendocrine tumours, lymphomas or squamous cell carcinomas. severe, active uncontrolled infection requiring systemic antibiotics, antiviral or antifungal treatments. any previous chemotherapy treatment for pancreatic cancer. eligible for resection of the pancreatic primary tumour but has either refused the operation or is considered to be medically unfit for the operation. clinical or CT evidence of central nervous system (CNS) metastases. any previous treatment with IMM101 or related mycobacterial immunotherapy. serum albumin &lt; 26 g/L. Creactive protein (CRP) &gt; 70 mg/L. radiotherapy in the 6 weeks prior to screening. depot corticosteroids in the 6 weeks prior to screening. chronic use of any systemic corticosteroids and/or immunosuppressant drugs within the 2week period prior to the first administration of study drug female patient of childbearing potential who is not, in the opinion of the Investigator, using an approved method of birth control (</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>